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doi:10.1016/j.joca.2010.01.007The Oxford English Dictionary1 deﬁnes a phenotype as the ‘‘sum
total of observable characteristics of an individual, regarded as the
consequences of the interaction of the individual’s genotype and
environment; a variety of an organism distinguished by observable
characteristics rather than underlying genetic features.’’ Wikipe-
dia2 expands this deﬁnition to‘‘any observable characteristic or trait
of an organism such as its morphology, development, biochemical,
or physiologic properties or behavior.’’ One key element of these
deﬁnitions is that a phenotype is deﬁned by a characteristic that
is observable by the naked eye, by images or by blood tests. A geno-
type is often the source of phenotypic variation, but a genotype is
only relevant to phenotypes when it creates an observable differ-
ence between two organisms with the same disease; thus a geno-
type expression can create phenotypic variation when the effect
of the genotype is observable.
Examples of phenotypes inmedicine include treatment deﬁning
phenotypes such as when a womanwith breast cancer has a tumor
that is estrogen-receptor positive and, therefore, is treated with
tamoxifen. If her tumor were estrogen-receptor negative, she
would not be so treated. Another example constitutes families
who inherit the BRCA (Breast Cancer Early Onset) gene which alters
the prevention approach to their breast cancer or ovarian cancer
and a third is when a phenotype alters the conceptualization of
disease biology such as whenMarshall suggested that gastric ulcers
might actually be caused by bacteria, a prophetic suggestion
conﬁrmed when the Helicobacter pylori bacterium was discovered
and characterized in ulcers.
The overall goal of this paper is to explore the existence of
distinct phenotypes in osteoarthritis (OA). To accomplish this
goal, I will posit criteria to use to deﬁne phenotypes and then
will suggest which phenotypes exist and which do not.
Ultimately, there are hundreds of phenotypes that could be
deﬁned in OA. To be meaningful for clinical practice and for epide-
miologic studies, phenotype distinctions should be conﬁned to
those that affect treatment or prevention decisions and to those
which clearly have a fundamental effect on the way we view
disease biology and/or disease etiology. Since our knowledge ofResearch Society International. Pudisease and our ability to observe or image aspects of disease are
continually changing, it is likely that new insights will, in turn,
support the existence of new or evolving phenotypes. Therefore,
any elaboration of disease phenotypes is necessarily limited to
current knowledge and technology.
The most common factors deﬁning phenotypes are risk or etio-
logic factors in addition to genetic variation. For example, hip OA
phenotypes are deﬁned based on developmental hip abnormalities
such as congenital dysplasia. Hips with developmental abnormali-
ties often need early surgeries and are, therefore, different pheno-
types than those without such early changes. Among the most
common factors, differentiating disease phenotypes is extent of
disease. In cancer, TNM staging systems (T for extent of tumor, N
for nodal involvement and M for metastasis) which describe the
extent and severity of a cancer often deﬁne different treatment
choices. For example, breast cancer that is small and limited in
scope within the breast might be treated with a lumpectomy,
whereas metastatic disease would require chemotherapy.
Since OA is widely regarded as a ﬁnal common pathway of joint
destruction for multiple different pathophysiologic etiologies
including trauma, developmental etiologies, primary cartilaginous
disorders, and even crystal-induced arthritis, differentiating these
etiologies might provide different phenotypes of OA. Identifying
different phenotypes in OA may be highly relevant to treatment
and prevention development in this disease. Therefore, isolating
phenotypes in OA may be critical to development of effective treat-
ment and disease prevention. If treatment works only in one
subtype, for example, a treatment targeted to bone marrow lesions,
wewill miss the therapeutic effect of that treatment if it is tested in
everyonewith OA, because many do not have bonemarrow lesions.
If, on the other hand, treatment does not work in a subset of disease
with a particular common feature, we may miss the effect of treat-
ment on the less common subset that does not have this feature. An
example of this might be if malalignment of the knee creates too
much focal stress for a chondroprotective agent to work. The
same considerations would be relevant for disease prevention as
for disease treatment.blished by Elsevier Ltd. All rights reserved.
Fig. 1. Percent of knee OA due to hypothesized causes of knee OA.
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sufﬁcient cause models (see Fig. 1). Each of these pie charts consti-
tutes a hypothetical cause of OA. For example, on the left, we could
hypothesize that 40% of knee OA was due to a combination of risk
factors including obesity, getting older, and being a women. Since
not all overweight, older women develop knee OA, an unknown
set of causes is also invoked. What is relevant about this particular
sufﬁcient cause pie is that if any of the causes is removed (e.g., if
obesity were eliminated), a sufﬁcient cause of disease would no
longer occur and knee OA prevalence would decrease. Thus, if
obesity were eliminated, up to 40% of knee OA would no longer
occur. The middle ﬁgure is another pie of disease caused by knee
injury along with age and combined with the usual unknown set
of causes because not all people with injury who are older get
OA. On the right, we postulate that roughly 15% of knee OA is due
to genetic causes and that genes could translate into a phenotype
if the effects of the gene created an observable characteristic,
a phenotype. The hypothetical pie charts depicted do not account
for 100% of knee OA, because there must be other causal pathways
that determine other phenotypes in disease.
The remainder of this paper will address three speciﬁc issues.
First, what is the evidence supporting the validity of widely used
phenotypes in OA? Second, what are other likely phenotypes, not
currently widely hypothesized as being phenotypes in OA? And
lastly, how will we determine and conﬁrm phenotype distinctions
that might be of importance in OA?The validity of widely used phenotypes
Generalized vs joint speciﬁc OA
The ﬁrst widely used phenotype in OA consists of differenti-
ating between generalized arthritis and joint speciﬁc disease.
Recent work from the consortia carrying out meta-analyses of
genome wide association studies in OA has suggested that there
is at least one polymorphism that is associated with a heightened
risk of generalized disease3 the GDF 5 allele. According to results
from both meta-analyses of Asian4 and European populations3, an
allele in the GDF 5 intron which decreases the quantity but does
not affect the structure of GDF 5, confers an increased risk of OA,
perhaps because it depletes cartilage of an anabolic stimulus or
because of effects on skeletal development. Heightened risks of
hip, knee and, to a lesser extent, hand OA, have been seen among
populations where this GDF 5 allele is carried. The GDF 5 results
suggest that there is a generalized entity, perhaps conferred by
genetic transmittal that increases the risk of OA in multiple joints.
Having said that, most studies examining the heritability of OA inpopulations5,6 have suggested that most heritability is conferred
by the inheritance of genes that confer a heightened risk of joint
speciﬁc and not generalized OA. Those families with hip OA trans-
mit an increased risk of hip OA but not of OA in other joints. The
same is true for OA in the hands to the point where even inheri-
tance of thumb based OA is separate from inheritance of OA in the
DIP (distal interphalangeal) and PIP (proximal interphalangeal)
hand joints5. Recently, MacGregor6and colleagues found no asso-
ciation at all between the genetic inheritance of OA in the DIP
joints and OA in the hips and almost no association between
hand and knee OA. This suggests that much of the genetic basis
for OA occurs on a joint speciﬁc basis and may relate to joint
shape or developmental abnormalities.
The genetics of OA provides evidence that both generalized
and joint speciﬁc phenotypes of OA exist, but that joint speciﬁc
disease, even driven by genetic considerations, may be the more
common.Secondary vs primary OA
OA due to identiﬁable causes, which by themselves can cause
disease without the contribution of other likely risk factors, has
been characterized as a separate phenotype from primary OA and
has been conceptualized as an uncommon cause of OA. Causes of
secondary OA include major joint injury, metabolic disorders, and
possibly crystal disease. OA, without an identiﬁable cause, is
labeled as primary disease.
The proportion of OA that is secondary is likely to be substan-
tially higher than previously believed. For example, in the Framing-
ham study, a community based sample of persons selected without
regard to knee OA or knee pain, 40–60% of older men had meniscal
tears on MRI, most of them incidental and unrelated to pain. Older
women also had a high rate of meniscal tears, although less than
men7. Englund et al.8 reported that these tears, often asymptomatic,
led to a marked increase risk in the development of OA over the
subsequent 30 months. (The tears could represent the ﬁrst
evidence of the OA process.) The high rate of OA among those
with incidental tears and the high prevalence of incidental tears
suggests that up to 50% of OA in the community may be due to
meniscal tear and that does not count minor and/or unrecognized
injuries that may predispose to the development of OA. The high
prevalence of metabolic factors, such as the existence of crystals
within the joint, which may also predispose to disease, suggests
that secondary OAmay bemore the rule than the exception, at least
for knee OA. Ultimately, as we better understand the pathogenesis
of OA in subsets of persons with disease, primary disease may
become a meaningless concept. Thus, this phenotypic distinction
Fig. 2. Percent of progressive knee OA among knee OA cases.
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pathogenesis of disease.
Incident vs progressive OA
In epidemiologic circles, the distinction is often made between
the new onset of the disease (incident disease) and the presence
of disease which can progress after it has occurred (progressive
disease). The distinction between these two stages of disease
depends onwhether disease can be clearly characterized as present
or absent (such medical conditions as hip fracture and myocardial
infarction are good examples of easily deﬁned disease incidence).
In OA, on the other hand, many persons in the community have
evidence of disease such as deﬁnite osteophytes in one joint, and
it is unclear who has disease and who does not nor when exactly
disease begins. Is disease present when there is a small osteophyte
without symptoms in one joint only, for example? Does it become
manifest when the osteophyte becomes larger and deﬁnite?
Deﬁning incidence and progression is challenging; and the distinc-
tion between these phenotypes is less clear-cut than is optimal.
Using thresholds to deﬁne the existence of disease is necessary;
in order to study disease, but recognition that these thresholds
that demarcate present disease from absent disease do not neces-
sarily represent distinct phenotypes is important.
Suggested phenotypes
Many persons with OA in the community do not have any
pain9 and would not necessarily want to be treated for a struc-
tural abnormality that is causing them no problems. Thus, it
might be useful to distinguish between those with painful vs
non-painful OA.
Among those with pain, there are a set of unique manifestations
that probably represent activation of the central nervous system to
create a chronic painful disorder with elements of dysfunctional
pain. These patients have receptor ﬁeld enlargement (the feeling
of pain beyond their joints) and often on testing have evidence of
generalized hypersensitivity to pain10. Such persons probably
should be recognized as having a separate phenotype as they
may need and respond to treatment that is different from that tar-
geted toward speciﬁc joint pain. Thus, it is useful to separate out
persons with OAwho have a painful disorder that includes dysfunc-
tional elements of pain and thosewith OA perhaps at a milder stage
who have functional pain only and do not have evidence of central
nervous system activation.
One suggested phenotype includes knees with malalignment
severe enough to drive the disease process. We have found
repeated evidence11–13 that knees that are sufﬁciently malaligned
progress to worse disease without the presence of other known
risk factors. For example, we have reported that obesity is not
a risk factor for progression of disease in knees that are malaligned,
whereas it is a risk factor among knees with OA that are in neutral
alignment11. Malalignment confers high focal stress, a level of stress
that probably transcends the ability of cartilage or bone within the
joint to withstand it. Evidence for this includes the strong associa-
tion of malalignment with the presence of bone marrow lesions14
which on histology are traumatic lesions to bone including
micro-cracks suggesting that malalignment actually damages
bone15. If this is so, it is likely that the overlying cartilage also is
damaged solely by malalignment. The implication for the presence
of this malaligned phenotype is that treatments targeted toward
cartilage protection are not likely to work in knees that are mala-
ligned. If conventional risk factors such as obesity do not confer
an increased risk in such malaligned knees, then it seems likely
that drugs to protect cartilage will be insufﬁciently effective toprevent progression in such knees (sufﬁcient cause Fig. 2). As
shown in the ﬁgure, malalignment itself is sufﬁcient to cause
progression of disease along with the usual unknown set of risk
factors; obesity and other known risk factors are not included in
this pie because they are not necessary to cause disease. This mala-
lignment based sufﬁcient cause accounts for up to 60% of knee OA
progression with the minority being accounted for by known risk
factors such as obesity and age.
Identifying and validating phenotypic distinctions
We next turn to approaches to conﬁrm these phenotypes and
identify yet other new phenotypes in OA. Epidemiologic and statis-
tical approaches to identify subtypes of disease include factor or
cluster analyses, statistical approaches which take a large popula-
tion and break them into clustered sub-groups within that popula-
tion. While ideal as a statistical tool, cluster and factor analyses
have not, by themselves, characterized a disease phenotype, but
have been used to corroborate ones that have been clinically identi-
ﬁed. Another theoretical approach would be to take a genomewide
association study that identiﬁed speciﬁc SNPs (single nucleotide
polymorphisms) as related to disease that then, in turn, identiﬁed
genes whose functions were known and then tested whether those
genes conferred a particular observable, distinct phenotype of
disease different from disease not caused by these genes.
Another approach to deﬁning subtypes of disease would include
the epidemiologic approaches used to characterize the malalign-
ment phenotype inwhich it was discovered that known risk factors
such as obesity did not operate when particular other risk factors
were present. If this can be conﬁrmed in multiple studies, then
that would identify a conﬁrmed subtype. Lastly and importantly,
biological understandings of disease are the most likely source for
identifying new phenotypes that can be tested then in clinical
populations.
Once subtypes have been hypothesized or identiﬁed, it is chal-
lenging to conﬁrm them. Conﬁrmation in independent studies is
absolutely critical. Ioannidis16 working in the genetics ﬁeld, has
noted that over 90% of initial reports of genetic associations are
not conﬁrmed in subsequent studies. This is also likely to be the
case for proposed subtypes in OA. The initial ﬁnding of a subtype
is often exciting, but conﬁrming that subtype in large, more deﬁn-
itive studies is often extremely challenging. The phenotype, as
noted earlier, must deﬁne response to treatment or prevention
strategy or must provide evidence that it is important for under-
standing biological differences among types of disease. Large
studies are best for both identifying subtypes and for conﬁrming
these subtypes.
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